Search the Newsreel

Jupiter Neurosciences (JUNS) Stock Forecast & Analyst Ratings

This article provides a stock forecast and analyst ratings for Jupiter Neurosciences (JUNS). It likely covers aspects such as price targets, current recommendations from analysts, and potential future performance. Investors can use this information to inform their decisions regarding the stock.

Perceptive Advisors LLC Takes $9.95 Million Position in Neumora Therapeutics, Inc. $NMRA

Perceptive Advisors LLC has acquired a significant stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA), purchasing over 5.1 million shares valued at approximately $9.95 million. This investment represents about 2.75% of the company, contributing to the 47.65% institutional ownership of Neumora Therapeutics. While analyst sentiment is …

Perceptive Advisors LLC Has $16.40 Million Stake in Contineum Therapeutics, Inc. $CTNM

Seven Fleet Capital Management LP Makes New Investment in Minerva Neurosciences, Inc $NERV

Neueon Corporation Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

NewMarket Corporation Reports Second Quarter and First Half 2026 Results

NewMarket Corporation reported strong financial results for the second quarter and first half of 2026, with net income increasing to $133.8 million for Q2 2026 and $251.8 million for H1 2026. The petroleum additives segment saw improved operating profit due to surcharges addressing higher …

Neuronetics’ Five New Hires Get RSUs Vesting Over 4 Years

Neuronetics (NASDAQ: STIM) has granted equity inducement awards in the form of restricted stock units (RSUs) to five new non-executive employees. These awards, made under the company's 2020 Inducement Incentive Plan and in accordance with Nasdaq Listing Rule 5635(c)(4), vest over three to four …

PMN|ProMIS Neurosciences Inc|Price:13.720|Chg%:-1.200

This article provides a comprehensive stock analysis of ProMIS Neurosciences Inc (PMN), highlighting its strong fundamentals and high growth potential. The company's valuation is considered fair, and institutional ownership is notably high. Analysts have issued "Buy" ratings, projecting a significant upside for the stock …

Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC), Alnylam Pharma (ALNY) and Fortrea Holdings Inc. (FTRE)

This article summarizes recent analyst ratings for three healthcare companies: Bicycle Therapeutics (BCYC), Alnylam Pharma (ALNY), and Fortrea Holdings Inc. (FTRE). Needham maintained a Buy rating for Bicycle Therapeutics, William Blair maintained a Buy for Alnylam Pharma, and Bank of America Securities maintained a …

Neurocrine Biosciences (NBIX) Is Down 5.1% After Q2 Earnings Beat And Higher INGREZZA Guidance – What's Changed

In the second quarter of 2026, Neurocrine Biosciences reported revenue of US$959.0 million and net income of US$144.4 million, sharply higher than a year earlier and ahead of analyst expectations, with INGREZZA, CRENESSITY, and newly acquired VYKAT XR leading record sales. The company also …

Neurocrine Biosciences (NBIX) Appoints Four Senior Leaders As Pipeline And Portfolio Expand

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Neurocrine Biosciences appointed a new Chief Business Officer and three Senior Vice Presidents to its senior leadership team. The moves come as the company …

RBC Capital Keeps Their Buy Rating on Contineum Therapeutics, Inc. Class A (CTNM)

Neurocrine Biosciences (NBIX) Lifts INGREZZA Guidance, Is The Pullback A Bargain?

Neurogene Inc. Revenue Breakdown – NASDAQ:NGNE

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Neuronetics, Inc. announced an inducement grant of restricted stock units (RSUs) to its new Chief Financial Officer, Matthew Bennett. This grant, totaling 167,490 RSUs, was made outside of the company's existing equity compensation plans but was approved by the Compensation Committee in accordance with …

Neurocrine Biosciences (NBIX) Stock Slides As Growth Spending Steals Focus

Neurocrine Biosciences (NBIX) stock dropped 10% despite strong Q2 2026 revenue and earnings, indicating the market is reacting to growth spending rather than current earnings. The company showed robust performance with INGREZZA and emerging products like CRENESSITY and VYKAT XR, but analysts are cautious …

Neuropace Inc (NPCE) Financial Health: Profitability & Balance Sheet Analysis

Neuropace Inc (NPCE) currently holds a financial score of 6.68, ranking 138 out of 200 in the Healthcare Equipment & Supplies industry, indicating a weak financial status and average operating efficiency. The company's latest quarterly revenue decreased by 2.02% year-over-year to $22.07M, with net …

Levi & Korsinsky Notifies Shareholders of Neumora Therapeutics, I

Levi & Korsinsky LLP has announced a class action lawsuit against Neumora Therapeutics, Inc. (NMRA) on behalf of shareholders who suffered losses. The lawsuit alleges that Neumora made false statements and concealed information regarding its Phase Three Program and Phase Two trial data for …

NeuroSense Therapeutics (NRSN) seeks reverse split amid Nasdaq compliance push

NeuroSense Therapeutics (NRSN) is calling a Special Meeting of Shareholders on August 26, 2026, to seek approval for a reverse stock split. This move is aimed at regaining compliance with Nasdaq's minimum bid price ($1.00) and market value of listed securities ($35 million) requirements, …

NeuroSense Therapeutics (NRSN) revises Capital on Demand share sales deal

NeuroSense Therapeutics has amended its Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC, updating the referenced registration statement to a new Form F-3 (File No. 333-293060), which became effective on July 31, 2026. Under the revised agreement, the company can offer and …

NEUP|Neuphoria Therapeutics Inc|Price:3.880|Chg%:-0.040

This article provides a comprehensive stock analysis of Neuphoria Therapeutics Inc (NEUP) from TradingKey. It highlights the company's strong fundamentals and high growth potential, despite its stock trading sideways between support and resistance levels. The analysis also covers its valuation, institutional ownership, analyst ratings, …

Neuberger fund's $0.12 payout may include return of capital

Neuberger Next Generation Connectivity Fund (NBXG) has declared a monthly distribution of $0.12 per share, payable on August 31, 2026, to shareholders of record on August 17, 2026. While the fund aims for stable monthly payouts, these distributions may include net investment income, capital …

Neurocrine Biosciences (NBIX) Is Down 5.2% After Earnings Beat And Raised INGREZZA Outlook Has The Bull Case Changed?

Neurocrine Biosciences reported strong Q2 2026 earnings with revenue of US$959.0 million and net income of US$144.4 million, and raised its INGREZZA sales guidance. Despite these positive results, the stock fell 5.2%, reflecting ongoing concerns about pricing pressure and product concentration risks within its …

Neurocrine Biosciences Q2 Earnings Call Highlights

Neurocrine Biosciences reported strong Q2 2026 revenues exceeding $950 million, a nearly 40% year-over-year increase, driven by INGREZZA and CRENESSITY sales, plus VYKAT XR's partial contribution. The company raised its full-year INGREZZA sales guidance and is integrating VYKAT XR following a $2.9 billion acquisition. …

Neurocrine Biosciences Inc (NBIX) Shares Fall 10.1% -- What GF S

Neurocrine Biosciences Inc (NBIX) shares dropped 10.1% to $166.80, yet GuruFocus estimates the stock is undervalued with a GF Value™ of $192.59. The company holds a strong GF Score™ of 94/100, driven by excellent growth potential, but faces caution due to significant insider selling …

Price to book forward of Neuropace, Inc. – NASDAQ:NPCE

This page provides financial information for Neuropace, Inc. (NASDAQ: NPCE), specifically focusing on its price to book forward ratio. It includes links to various financial data, news, and community sections related to the company on the TradingView platform.

Neurocrine Biosciences (NBIX) quantifies Soleno acquisition and VYKAT XR impact

Aspen's Parkinson's Cell Therapy Gets FDA RMAT Designation—Not Approval

ClearPoint Neuro announced that its partner Aspen Neuroscience received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for sasineprocel, an investigational Parkinson's disease therapy. This designation expedites development and review but does not constitute FDA approval. ClearPoint Neuro's Navigation System and SmartFlow Cannula are utilized …

Trading the Move, Not the Narrative: (NPCE) Edition

This article provides an AI-driven analysis of Neuropace Inc. (NPCE), highlighting weak near and mid-term sentiment despite a positive long-term outlook. It presents three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis emphasizes elevated downside risk …

(NEU) Volatility Zones as Tactical Triggers

This article analyzes Newmarket Corp (NEU) using AI models, identifying strong near and mid-term sentiment, and potential for long-term growth. It provides three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis also includes multi-timeframe signal …

(NBXG) Price Dynamics and Execution-Aware Positioning

This article analyzes the price dynamics and execution-aware positioning for Neuberger Berman Next Generation Connectivity Fund Inc. (NASDAQ: NBXG). It highlights weak near and mid-term sentiment potentially challenging a long-term positive outlook, identifies a mid-channel oscillation pattern, and outlines distinct trading strategies with risk …

Neuropace, Inc. Revenue Breakdown – NASDAQ:NPCE

Neuropace, Inc. (NASDAQ: NPCE) generated $99.99 million in revenue last year, primarily from its Medical Device segment, which contributed the entire amount. This marks an increase from $79.91 million in the previous year. The United States was the company's largest market, accounting for all …

ClearPoint Neuro Congratulates Partner Aspen Neuroscience on FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasineprocel

ClearPoint Neuro congratulates its partner Aspen Neuroscience on receiving the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation for sasineprocel (ANPD001), an investigational autologous cell replacement therapy for Parkinson's disease. This designation will support an expedited development and review pathway for Aspen's therapy, which utilizes …

Neurocrine Biosciences Slides as Q2 Results and Outlook Leave Little Room for Upside

Neurocrine Biosciences (NBIX) stock fell 10.0% following its Q2 2026 earnings release, which investors viewed as mixed rather than exceeding expectations. Despite solid demand for key products like INGREZZA, the company largely reaffirmed its existing outlook instead of raising guidance, leading to investor disappointment. …

Scancell merges with Nasdaq shell Neuphoria to fund USD 89m Phase III melanoma trial

UK-based Scancell Holdings plc has announced an all-share merger agreement with Neuphoria Therapeutics Inc., a move that will provide Scancell with a Nasdaq listing and up to $89 million in financing. This funding is earmarked for the registrational Phase III development of Scancell's melanoma …

Neurocrine Biosciences, Inc. Stock 12‑Month Price Target Raised to $209.63, Implies 13% Upside

Neurocrine Biosciences, Inc. (NBIX) has seen its average 12-month stock price target increased from $201.2 to $209.34 by 28 analysts, implying a potential 13% upside based on the July 30 closing price. The consensus rating among 31 covering analysts remains a "Buy," with 27 …